Append Medical, an Or Yehuda, Israel-based developer of a device designed to close the LAA in a transcatheter procedure without requiring any metal implants, raised $4.35m as part of an extended series A round.
Investors included participants from the first tranche of the A round as well as new investors, Shoni Health Ventures and ALIVE Israel HealthTech Fund.
The company intends to use the funds to complete the development of and support the First-in-Human Study of the Appligator™ for the Prevention of Stroke in Atrial Fibrillation Patients.
Founded in 2018 by Dr. Zachi Berger and based on the idea of Dr. Leonid Sternik from Sheba Medical Center, and led by CEO Mr. Nadav Agian, Append Medical is developing the Appligator™, a device designed to completely close the LAA in a transcatheter procedure without requiring any metal implants.
It is a portfolio company of the MEDX Xelerator, an Israeli medical device incubator.
FinSMEs
06/07/2023